Novel vasopressin V1A and V2 antagonist (Conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia

被引：0
|
作者：
Verbalis, JG
Bisaha, JG
Smith, N
机构：
[1] Yamanouchi Pharma Amer Inc, Paramus, NJ USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3346
引用
收藏
页码：723 / 723
页数：1
相关论文
共 50 条
  • [41] Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith, Steven R.
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 : S93 - S96
  • [42] Alterations of renal vasopressin V1A and V2 receptors in spontaneously hypertensive rats
    Tahara, A
    Tsukada, J
    Tomura, Y
    Wada, K
    Kusayama, T
    Ishii, N
    Yatsu, T
    Uchida, W
    Taniguchi, N
    Tanaka, A
    PHARMACOLOGY, 2003, 67 (02) : 106 - 112
  • [43] Mutagenesis of endogenous cysteine residues in human V1a and V2 vasopressin receptors
    Loh, ED
    Tharian, A
    Pratt, B
    Johnson, MP
    Kolakowski, LF
    FASEB JOURNAL, 1997, 11 (09): : A1340 - A1340
  • [44] Coupling between V1a and V2 vasopressin receptor transduction pathways.
    Klingler, C
    Barrault, MB
    Ancellin, N
    Morel, A
    Corman, B
    Friedlander, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A0103 - A0103
  • [45] A novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia
    Jennings, Douglas L.
    Kalus, James S.
    FORMULARY, 2008, 43 (07) : 236 - +
  • [46] The magnocellular vasopressin neurones of the rat hypothalamus express V1a and V1b but not V2 vasopressin receptor mRNAs
    Hurbin, A
    Boissin-Agasse, L
    Orcel, H
    Rabié, A
    Joux, N
    Desarménien, MG
    Richard, P
    Moos, FC
    JOURNAL OF PHYSIOLOGY-LONDON, 1998, 509P : 87P - 87P
  • [47] Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Shin Nakayama
    Mahmood Amiry-Moghaddam
    Ole Petter Ottersen
    Anish Bhardwaj
    Neurocritical Care, 2016, 24 : 273 - 282
  • [48] Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?
    Goldsmith, Steven R.
    Udelson, James E.
    Gheorghiade, Mihai
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (02) : 112 - 114
  • [49] Use of Oral Vasopressin V2 Receptor Antagonist for Hyponatremia in Acute Brain Injury
    Jeon, Sang-Beom
    Choi, H. Alex
    Lesch, Christine
    Kim, Myung Chun
    Badjatia, Neeraj
    Claassen, Jan
    Mayer, Stephan A.
    Lee, Kiwon
    EUROPEAN NEUROLOGY, 2013, 70 (3-4) : 142 - 148
  • [50] LIXIVAPTAN Vasopressin V2 Receptor Antagonist Treatment of Heart Failure Treatment of Hyponatremia
    Daifallah, S.
    Zmily, H. D.
    Alqwasmi, A. H.
    Zayed, H.
    Ghali, J. K.
    DRUGS OF THE FUTURE, 2011, 36 (05) : 359 - 370
12345